Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- Africa Remains Significantly Underrepresented in Clinical TrialsAfrican populations remain markedly underrepresented in the randomized controlled trials (RCTs) that shape global cardiovascular care, according to a new systematic review of studies published between 2019 and 2024 in leading general and cardiovascular journals.
- ACC CardiaCast: Improving Early FH Detection and Management From the ExpertsIn this episode, Drs. Christie Ballantyne and Anne Goldberg discuss updates on familial hypercholesterolemia (FH) diagnosis and management.
- COBRRA: Bleeding Risk Lower With Apixaban Than Rivaroxaban in VTE at 3 MonthsThe risk of clinically relevant bleeding was significantly lower with apixaban compared with rivaroxaban among patients with acute venous thromboembolism (VTE) during a three-month treatment period, according to results of the COBRRA trial published March 11 in NEJM.
- Is Epicardial Adipose Tissue Volume an Indicator of CAD?A recent study published in JACC: Cardiovascular Imaging found that high epicardial adipose tissue volume (EATv) is independently associated with the presence and progression of coronary artery disease (CAD), highlighting its value as a potential risk stratification marker for major cardiovascular events (MACE) and a therapeutic target for earlier or more intensive intervention.
- DOBERMANN: Are Tocilizumab, Dobutamine Effective in Reducing CS Risk in Patients With AMI?Two brief reports in JACC on the DOBERMANN-T and DOBERMANN-D trials found that among patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), early interleukin 6 (IL 6) receptor inhibition with tocilizumab safely reduced systemic inflammation but showed inconclusive effects on NT proBNP. In contrast, early dobutamine infusion did not lower […]